Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Malignant melanoma
ADR ID BADD_A02651
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.03      Skin neoplasms malignant and unspecified
16.03.01      Skin melanomas (excl ocular)
16.03.01.001      Malignant melanoma
23      Skin and subcutaneous tissue disorders
23.08      Skin neoplasms malignant and unspecified
23.08.01      Skin melanomas (excl ocular)
23.08.01.001      Malignant melanoma
Description A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) [MeSH]
MedDRA Code 10025650
MeSH ID D008545; D018328
ADR Severity Grade (FAERS) Not Available
ADR Severity Grade (CTCAE) Not Available
Synonym
Lentigo melanoma | Malignant melanoma | Malignant melanoma of other specified sites of skin | Malignant melanoma of skin | Malignant melanoma of skin of ear and external auditory canal | Malignant melanoma of skin of ear and external auricular canal | Malignant melanoma of skin of lip | Malignant melanoma of skin of lower limb, including hip | Malignant melanoma of skin of other and unspecified parts of face | Malignant melanoma of skin of scalp and neck | Malignant melanoma of skin of trunk, except scrotum | Malignant melanoma of skin of upper limb, including shoulder | Malignant melanoma of skin stage unspecified | Malignant melanoma site/stage unspecified | Melanoma limited to extremity | Melanoma malignant | Melanoma of skin (malignant) | Melanoma of skin, site unspecified | Melanoma of trunk and head | Melanoma skin | Skin melanoma | Melanoma malignant aggravated | Cervical melanoma | Melanoma | Malignant melanoma of skin of lower limb, incl hip | Malignant melanoma of skin of upper limb, incl shoulder | Malignant melanoma of skin of trunk, excl scrotum | Blue naevus-like melanoma | Angiotropic melanoma | Blue nevus-like melanoma | Amelanotic melanoma | Melanoma non-resectable | Cutaneous melanoma | Melanomas | Malignant Melanoma | Malignant Melanomas | Melanoma, Malignant | Melanomas, Malignant
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01478Mitomycin0.000168%
BADD_D01507Mycophenolate mofetil--
BADD_D01508Mycophenolic acid--
BADD_D01567Nilotinib0.000526%
BADD_D01679Paroxetine--
BADD_D01773Pimecrolimus--
BADD_D01817Pramipexole--
BADD_D01818Pramipexole dihydrochloride--
BADD_D01831Prednisolone0.000122%
BADD_D01834Prednisone--
BADD_D01835Pregabalin--
BADD_D01858Propagermanium--
BADD_D01898Rabeprazole--
BADD_D01909Ramipril0.000466%
BADD_D01916Rasagiline mesylate--
BADD_D01948Riociguat--
BADD_D01952Ritonavir--
BADD_D01966Ropinirole--
BADD_D01974Rotigotine hydrochloride--
BADD_D01978Ruxolitinib0.000412%
BADD_D02002Selegiline--
BADD_D02018Sildenafil0.022978%
BADD_D02028Sirolimus--
BADD_D02029Sitagliptin0.000080%
BADD_D02047Sodium oxybate0.000805%
BADD_D02104Tacrine hydrochloride--
BADD_D02105Tacrolimus0.000891%
BADD_D02106Tadalafil0.009076%
BADD_D02165Teriflunomide0.001206%
BADD_D02192Thalidomide0.000723%
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
ADR Term Drug Name Target